Compare BioNano Genomics Inc (BNGO) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Consumer Discretionary Select Sector SPDR Fund trades at $116.51. The key difference: Consumer Discretionary Select Sector SPDR Fund is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | XLY | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | — |
52-Week High | $4.92 | $124.52 |
52-Week Low | $1.09 | $105.64 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
XLY trades at $116.04, down 1.02% today amid a bearish technical signal with selling pressure outweighing buys 12 to 4. Analyst consensus is unanimously bullish with a 100% buy rating. Recent news highlights consumer discretionary as a potential sleeper opportunity for Q3 2026, though inflation and weak consumer sentiment pose headwinds. The stock shows neutral oscillators but bearish moving averages, with support at $114 and resistance at $118.
The outlook for XLY is cautiously optimistic given strong analyst support, but risks include persistent inflation eroding discretionary spending and technical weakness. Investment opportunity hinges on a consumer spending rebound, while key risks are macroeconomic pressures and sector underperformance. The dividend scheduled for June 2026 offers minor income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
